ES2823589T3 - Formulaciones farmacéuticas para la administración subcutánea de furosemida - Google Patents

Formulaciones farmacéuticas para la administración subcutánea de furosemida Download PDF

Info

Publication number
ES2823589T3
ES2823589T3 ES14778339T ES14778339T ES2823589T3 ES 2823589 T3 ES2823589 T3 ES 2823589T3 ES 14778339 T ES14778339 T ES 14778339T ES 14778339 T ES14778339 T ES 14778339T ES 2823589 T3 ES2823589 T3 ES 2823589T3
Authority
ES
Spain
Prior art keywords
furosemide
pharmaceutical formulation
tris
liquid pharmaceutical
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14778339T
Other languages
English (en)
Spanish (es)
Inventor
Scott Michaels
Pieter Muntendam
Glenn Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ScPharmaceuticals Inc
Original Assignee
ScPharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ScPharmaceuticals Inc filed Critical ScPharmaceuticals Inc
Application granted granted Critical
Publication of ES2823589T3 publication Critical patent/ES2823589T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES14778339T 2013-04-05 2014-04-03 Formulaciones farmacéuticas para la administración subcutánea de furosemida Active ES2823589T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (1)

Publication Number Publication Date
ES2823589T3 true ES2823589T3 (es) 2021-05-07

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14778339T Active ES2823589T3 (es) 2013-04-05 2014-04-03 Formulaciones farmacéuticas para la administración subcutánea de furosemida

Country Status (14)

Country Link
US (5) US9884039B2 (enExample)
EP (2) EP2981258B8 (enExample)
JP (2) JP6415535B2 (enExample)
KR (2) KR102493735B1 (enExample)
CN (1) CN105431145B (enExample)
AU (1) AU2014248164B2 (enExample)
CA (1) CA2908935C (enExample)
DK (1) DK2981258T3 (enExample)
ES (1) ES2823589T3 (enExample)
IL (1) IL241917B (enExample)
MX (1) MX367165B (enExample)
PT (1) PT2981258T (enExample)
SG (2) SG10201709388QA (enExample)
WO (1) WO2014165660A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2981258B8 (en) * 2013-04-05 2020-11-11 scPharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
WO2020120482A1 (en) * 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
CN113271923B (zh) * 2019-01-04 2025-05-13 Sq创新股份公司 呋塞米的药物组合物及其用途
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
CA3190585A1 (en) 2020-08-05 2022-02-10 Scpharmaceuticals Inc. Methods of treatment using furosemide
CA3215872A1 (en) 2021-04-02 2022-10-06 Scpharmaceuticals Inc. Subcutaneous infusion of furosemide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
CA2109924A1 (en) * 1991-05-30 1992-12-10 Janina Adamczyk Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ES2313266T3 (es) 2005-12-28 2009-03-01 Sensile Pat Ag Microbomba.
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
AR071810A1 (es) 2008-05-16 2010-07-14 Corthera Inc Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
CA2735660C (en) * 2008-09-09 2017-05-30 Cima Labs Inc. Dosage forms for weakly ionizable compounds
WO2011028997A1 (en) * 2009-09-04 2011-03-10 Minipumps Llc Adhesive skin patch with pump for subcutaneous drug delivery
BR112014009634A2 (pt) 2011-10-19 2017-05-09 Mercator Medsystems Inc preparação e agente terapêutico
EP2981258B8 (en) 2013-04-05 2020-11-11 scPharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide

Also Published As

Publication number Publication date
US11433044B2 (en) 2022-09-06
JP2019001821A (ja) 2019-01-10
KR102493735B1 (ko) 2023-01-30
IL241917B (en) 2020-10-29
CN105431145A (zh) 2016-03-23
WO2014165660A1 (en) 2014-10-09
SG11201508251RA (en) 2015-11-27
US10272064B2 (en) 2019-04-30
BR112015025204A2 (pt) 2021-03-16
US12370168B2 (en) 2025-07-29
PT2981258T (pt) 2020-10-19
JP6415535B2 (ja) 2018-10-31
US20200038364A1 (en) 2020-02-06
MX2015014064A (es) 2017-04-13
KR102266460B1 (ko) 2021-06-17
DK2981258T3 (da) 2020-10-19
EP2981258B8 (en) 2020-11-11
CA2908935C (en) 2021-06-15
CA2908935A1 (en) 2014-10-09
AU2014248164A1 (en) 2015-10-15
CN105431145B (zh) 2019-12-10
SG10201709388QA (en) 2017-12-28
KR20210075211A (ko) 2021-06-22
JP2016515623A (ja) 2016-05-30
US20160051507A1 (en) 2016-02-25
AU2014248164B2 (en) 2019-05-23
US20250339397A1 (en) 2025-11-06
JP6677779B2 (ja) 2020-04-08
EP2981258A1 (en) 2016-02-10
EP3799869B1 (en) 2025-08-27
US9884039B2 (en) 2018-02-06
US20180303790A1 (en) 2018-10-25
EP2981258A4 (en) 2016-10-05
KR20160014592A (ko) 2016-02-11
MX367165B (es) 2019-08-07
HK1221152A1 (zh) 2017-05-26
EP2981258B1 (en) 2020-08-12
US20230201156A1 (en) 2023-06-29
EP3799869A1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
ES2823589T3 (es) Formulaciones farmacéuticas para la administración subcutánea de furosemida
JP6796638B2 (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
CN100569230C (zh) 含有双氯芬酸钠和β-环糊精的可注射药物组合物
CN101708157B (zh) 一种单硝酸异山梨酯氯化钠注射液
WO2017177160A1 (en) Formulation for use in a method of treatment of pain
KR101353443B1 (ko) 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
KR20210150360A (ko) 푸로세미드의 농축된 액체 제약 제제 및 그의 투여 방법
US20200338082A1 (en) Formulations, systems, and methods for therapeutic treatment
CN105566100A (zh) 一种苯乙烯酸类化合物,包含其的组合物及其应用
HK40049405A (en) Pharmaceutical formulations for subcutaneous administration of furosemide
WO2022109052A1 (en) Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators
WO2009157010A1 (en) An intravenous drug delivery system
CN101601653B (zh) 泼尼卡酯脂质体乳膏
CA3191276A1 (en) Ionic liquid formulations for treating diabetes
BR112015025204B1 (pt) Formulação farmacêutica líquida de furosemida e seu uso
HK1221152B (en) Pharmaceutical formulations for subcutaneous administration of furosemide
EA046008B1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
CN104138351A (zh) 他克莫司非水凝胶